Quest Diagnostics/$DGX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Quest Diagnostics
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Ticker
$DGX
Sector
Primary listing
NYSE
Employees
50,500
Headquarters
Website
DGX Metrics
BasicAdvanced
$21B
21.96
$8.51
0.56
$3.15
1.71%
Price and volume
Market cap
$21B
Beta
0.56
52-week high
$197.55
52-week low
$148.70
Average daily volume
1.1M
Dividend rate
$3.15
Financial strength
Current ratio
1.128
Quick ratio
0.886
Long term debt to equity
77.345
Total debt to equity
86.524
Dividend payout ratio (TTM)
35.81%
Interest coverage (TTM)
5.61%
Profitability
EBITDA (TTM)
2,141
Gross margin (TTM)
33.45%
Net profit margin (TTM)
8.93%
Operating margin (TTM)
14.57%
Effective tax rate (TTM)
22.68%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
6.12%
Return on equity (TTM)
14.35%
Valuation
Price to earnings (TTM)
21.957
Price to revenue (TTM)
1.925
Price to book
2.86
Price to tangible book (TTM)
-6.28
Price to free cash flow (TTM)
14.998
Free cash flow yield (TTM)
6.67%
Free cash flow per share (TTM)
12.465
Dividend yield (TTM)
1.68%
Forward dividend yield
1.71%
Growth
Revenue change (TTM)
13.74%
Earnings per share change (TTM)
14.49%
3-year revenue growth (CAGR)
1.77%
10-year revenue growth (CAGR)
3.72%
3-year earnings per share growth (CAGR)
-5.83%
10-year earnings per share growth (CAGR)
5.72%
3-year dividend per share growth (CAGR)
6.61%
10-year dividend per share growth (CAGR)
7.92%
What the Analysts think about DGX
Analyst ratings (Buy, Hold, Sell) for Quest Diagnostics stock.
DGX Financial Performance
Revenues and expenses
DGX Earnings Performance
Company profitability
DGX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Quest Diagnostics stock?
Quest Diagnostics (DGX) has a market cap of $21B as of November 15, 2025.
What is the P/E ratio for Quest Diagnostics stock?
The price to earnings (P/E) ratio for Quest Diagnostics (DGX) stock is 21.96 as of November 15, 2025.
Does Quest Diagnostics stock pay dividends?
Yes, the Quest Diagnostics (DGX) stock pays dividends to shareholders. As of November 15, 2025, the dividend rate is $3.15 and the yield is 1.71%. Quest Diagnostics has a payout ratio of 35.81% on a trailing twelve-month basis.
When is the next Quest Diagnostics dividend payment date?
The next Quest Diagnostics (DGX) dividend payment is scheduled for January 28, 2026.
What is the beta indicator for Quest Diagnostics?
Quest Diagnostics (DGX) has a beta rating of 0.56. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.